Shanghai General Hospital
Shanghai General Hospital
Shanghai, China35 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) | Primary Membranous Nephropathy | Recruiting | Phase 2 / Phase 3 | 2026-09-18 | NCT07204275 | |
| Study of SGC001 Injection for Predicted Severe Acute Pancreatitis to Assess Safety, Tolerability and Preliminary Efficacy | Digestive System Diseases, acute pancreatitis, pancreas disorder, pancreatitis | Not yet recruiting | Phase 2 | 2026-09-04 | NCT07803965 | |
| Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis | Skin Diseases, Eczematous, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, dermatitis, sebaceous gland disorder, seborrheic dermatitis, skin disorder | Not yet recruiting | Phase 3 | 2026-08-21 | NCT07683806 | |
| A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma. | B-cell neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 1 | 2026-08-14 | NCT06970496 | |
| A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, arthropathy, connective tissue neoplasm, disease of the tendon, giant cell tumor, muscle tissue disorder, musculoskeletal system disorder, neoplasm, synovitis, tenosynovial giant cell tumor | Active, not recruiting | Phase 3 | 2026-06-26 | NCT04488822 | |
| CGM for Insulin-Treated T2DM During Post-Discharge Transition | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Recruiting | Not applicable | 2026-06-24 | NCT07414277 | |
| Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma | Recruiting | Early phase 1 | 2026-06-03 | NCT07439120 | |
| AI vs. Physician for Anti-VEGF Decision-Making: An RCT | Embolism and Thrombosis, Venous Thrombosis, cardiovascular disorder, eye disorder, macular degeneration, retinal degeneration, retinal disorder, retinal vein occlusion, thrombotic disease, vascular disorder | Not yet recruiting | Not applicable | 2026-05-22 | NCT07328776 | |
| Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Active, not recruiting | Phase 3 | 2026-05-15 | NCT06564142 | |
| Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis | ASCVD; ASCVD Management; Atherosclerosis Cardiovascular Disease | Recruiting | Phase 2 | 2026-04-28 | NCT07303777 | |
| Early-phase Study of ART002g1 Injection in HeFH: Safety, Tolerability and Preliminary Efficacy | Heterozygous Familial Hypercholesterolemia | Not yet recruiting | Early phase 1 | 2026-03-17 | NCT07353398 | |
| Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients | Diabetic Macular Edema (DME) | Recruiting | Early phase 1 | 2026-03-10 | NCT07362927 | |
| Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS) | eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Phase 2 | 2026-03-06 | NCT06196840 | |
| Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations | Inherited Retinal Dystrophy Associated With RPE65 Mutations | Active, not recruiting | Phase 1 | 2026-03-06 | NCT06196827 | |
| Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations | Inherited Retinal Dystrophy Associated With RPE65 Mutations | Active, not recruiting | Phase 3 | 2026-03-05 | NCT07054632 | |
| A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Not yet recruiting | Phase 2 | 2026-02-27 | NCT07436221 | |
| Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-02-09 | NCT04639986 | |
| The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT) | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 2 / Phase 3 | 2026-01-30 | NCT06921486 | |
| Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture | Bone Diseases, Metabolic, Nutritional and Metabolic Diseases, Osteoporotic Fractures, bone disorder, bone fracture, injury, metabolic disease, musculoskeletal system disorder, osteoporosis | Recruiting | Not applicable | 2026-01-12 | NCT05866029 | |
| A Study of Single Dose of LP-003 in Healthy Adult Subjects | Chronic Disease, Chronic Spontaneous Urticaria, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticaria | Active, not recruiting | Phase 1 | 2025-12-18 | NCT06604949 | |
| Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma | Hemic and Lymphatic Diseases, Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, extranodal nasal NK/T cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm | Recruiting | Early phase 1 | 2025-12-02 | NCT07162012 | |
| Low-Dose vs Standard-Dose Indomethacin for Preventing Post-ERCP Pancreatitis | Post-ERCP Pancreatitis | Recruiting | Phase 4 | 2025-11-18 | NCT07088757 | |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Diseases, autoimmune disease, connective tissue disorder, glomerulonephritis, immune system disorder, kidney disorder, lupus nephritis, membranous glomerulonephritis, nephritis, systemic lupus erythematosus, urinary system disorder | Recruiting | Phase 2 | 2025-11-18 | NCT07038382 | |
| Clinical Study of 177Lu-CTR-FAPI In the Treatment of Patients With Advanced, Metastatic Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Early phase 1 | 2025-11-17 | NCT07229768 | |
| A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. | Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | Recruiting | Phase 2 | 2025-08-17 | NCT06434597 |